Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo trial aims to boost fight against Virus-Linked cancer

NCT ID NCT07348575

Summary

This study is testing if adding a drug called decitabine to the standard chemotherapy regimen (R-CHOP) works better for treating a specific type of aggressive lymphoma that is linked to the Epstein-Barr virus (EBV). It will involve 80 adults who are newly diagnosed and have not yet received treatment. The main goal is to see if the new combination helps keep the cancer from coming back for a longer period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE-CELL, DIFFUSE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330000, China

Conditions

Explore the condition pages connected to this study.